FULL PAPER British Journal Cancer 2015 112 514522 doi 101038bjc2014659 Keywords pancreatic cancer oncogenic KRAS signalling pathway hypoxia clinicopathological predictors prognostic biomarkers Combining clinicopathological predictors molecular biomarkers oncogenic KRASKi67HIF1a pathway predict survival resectable pancreatic cancer R Qin19 T C Smyrk29 N R Reed39 R L Schmidt45 T Schnelldorfer3 S T Chari67 G M Petersen1 A H Tang348 1Department Health Sciences Research Mayo Clinic Cancer Center Mayo Clinic Rochester MN 55905 USA 2Division Anatomic Pathology Department Laboratory Medicine Pathology Mayo Clinic Cancer Center Mayo Clinic Rochester MN 55905 USA 3Department Surgery Mayo Clinic Cancer Center Mayo Clinic Rochester MN 55905 USA 4Department Biochemistry Molecular Biology Mayo Clinic Cancer Center Mayo Clinic Rochester MN 55905 USA 5Upper Iowa University IA 52142 USA 6Department Medicine Mayo Clinic Cancer Center Mayo Clinic Rochester MN 55905 USA Fayette 7Department Oncology Mayo Clinic Cancer Center Mayo Clinic Rochester MN 55905 USA 8Department Microbiology Molecular Cell Biology Leroy T Canoles Jr Cancer Research Center Eastern Virginia Medical School Norfolk VA 23507 USA Background The dismal prognosis patients diagnosed pancreatic cancer points limited arsenal effective anticancer therapies Oncogenic KRAS hyperactivation virtually universal pancreatic cancer confers drug resistance drives aggressive tumorigenesis rapid metastasis Pancreatic tumours marked hypovascularity increased hypoxia ineffective drug delivery Thus biomarker discovery developing innovative means countervailing oncogenic KRAS activation urgently needed Methods Tumour specimens 147 pancreatic cancer patients analysed immunohistochemical IHC staining tissue microarray TMA Statistical correlations selected biomarkers clinicopathological predictors examined predict survival Results We heightened hypoxia response predicts poor clinical outcome resectable pancreatic cancer SIAH biomarkers EGFR phosphoERK SIAH Ki67 HIF1a tumourspecific biomarker The combination clinicopathological predictors tumour size pathological grade margin lymph node status predict patient survival post surgery pancreatic cancer Conclusions Combining biomarkers KRASKi67HIF1a pathways clinicopathological predictors assist better predict survival resectable pancreatic cancer Pancreatic cancer fourth leading cause cancerrelated death United States dismal 5year survival rate 56 Siegel et al 2013 Clinical symptoms associated pancreatic ductal adenocarcinomas PDAC manifest late diagnosis local invasion systemic metastasisculminating dismal prognosis poor survival Wolfgang et al 2013 Surgical Correspondence Professor A Tang Email TangAHevmsedu 9These authors share co1st authorship equal contribution Revised 25 November 2014 accepted 10 December 2014 published online 13 January 2015 2015 Cancer Research UK All rights reserved 0007 092015 514 wwwbjcancercom DOI101038bjc2014659 Hypoxia reduces prognosis pancreatic cancer BRITISH JOURNAL OF CANCER resection offers best hope increased survival disease discovered local distant metastasis Sohn et al 2000 However minority patients B15 eligible surgical resection time diagnosis Hidalgo 2010 Even resectable tumours frequently experience postsurgery relapse succumbing deadly malignancy Katz et al 2009 Adjuvant therapies confer limited modest benefit Conroy et al 2011 Valle et al 2014 As result urgent need discover new biomarkers aiding prognosis develop curative strategies pancreatic cancer Maitra Hruban 2008 The cancer genomesequencing project reaffirmed para mount importance oncogenic KRAS activation human cancer Vogelstein et al 2013 The mitogenactivated protein kinase MAPKERK cascade activated human cancer SeboltLeopold Herrera 2004 Previous studies suggested upregulation phosphoERK associated reduced survival pancreatic cancer Javle et al 2007 Ectopic expression EGFR pancreatic cancer linked accelerated tumour growth increased metastasis poor survival Ardito et al 2012 Pancreatic cancer known desmoplastic hypovascularised treatmentresistant Von Hoff et al 2009 increased expression hypoxia inducible factor 1a HIF1a alter cellular metabolism aid tumour growth increase cancer survival hypoxic nutrientdeprived tumour environment Akakura et al 2001 SpivakKroizman et al 2013 active ERK tumorigenesis Many genes evaluated prognostic biomarkers pancreatic cancer unreliable inconsistent clinical validations Sawyers 2008 Costello et al 2012 Winter et al 2013 As requires multiple molecular alterations progress logical combination biomarkers main tumourpromoting signalling pathways improve prognostic accuracy Here examined prognostic value biomarkers upstream receptors EGFR HER2 midstream kinase phosphoERK KRAS downstream signalling gate keeper SIAH E3 ligase Schmidt et al 2007 Ahmed et al 2008 tumour proliferation index Ki67 hypoxic response indicator HIF1a human pancreatic cancer Along clinico pathological predictors focused oncogenic KRASKi67 HIF1a pathways evaluating prognostic value aforementioned biomarkers SIAH new tumourspecific biomarker pancreatic cancer We report combining biomarkers EGFR phosphoERK SIAH HIF1a Ki67 existing clinicopathological predictors tumour size pathological grade margin lymph node status clearly predictive patient survival Importantly increased expression HIF1a predict poor prognosis pancreatic cancer MATERIALS AND METHODS Ethical statement This study conducted ethical committee approval Mayo Clinic Institutional Review Board Informed consent obtained pancreatic cancer patients surgeries Mayo Clinic Patients Patients underwent surgical resection PDAC Mayo Clinic Rochester MN 1985 2001 study n ¼ 147 Patients underwent included pancreaticoduodenectomy n ¼ 129 distal pancreatectomy n ¼ 8 total pancreatectomy n ¼ 10 Clinical pathologic variables extracted patients medical records Table 1 Nineteen patients 129 lost followup survival times censored time known contact 2007 Pathologic samplestissue microarray TMA Biospecimens 134 pancreatic cancer patients construct TMA Owing tumour heterogeneity patients tumour specimen represented distinct pathologically confirmed tumour cores diameter ¼ 06 mm TMA The numbers TMA tissue cores patients statistical analyses summarised Table 2 Tumour biospecimens 13 pancreatic cancer patients distinct pathological stages Hruban et al 2000 validate TMA results Normal pancreas pancreatitis tissues served negative controls All tissue cores histology sections carefully reviewed expert pathologist double blind manner classified normal pancreas n ¼ 7 pancreatitis n ¼ 20 PanIN1 n ¼ 35 PanIN2 n ¼ 20 PanIN3 n ¼ 15 adenocarcinoma ADCA 2 n ¼ 84 ADCA 3 n ¼ 161 ADCA 4 n ¼ 33 Fivemicrometre sections cut TMA slide deparaffinised standard techniques placed 10 mM EDTA pH 80 30 min 100 1C antigen retrieval Staining conducted monoclonal antiEGFR antibody prediluted Dako Glostrup Denmark monoclonal antiphosphoERK 1 750 dilution Cell Signaling Danvers MA USA monoclonal antiHER2 prediluted Dako monoclonal antiHIF1a 1 250 dilution Novus Biologicals Littleton CO USA monoclonal antiKi67 1 100 dilution Dako monoclonal antiSIAH antibodies 1 40 dilution Novus Biologicals Schmidt et al 2007 A boardcertified pathologist 32 years experience pancreatic cancer scored reviewed TMA slides immunohistochemical IHC staining Percent staining scores measured core Scores averaged tissue cores tumour yield single percent staining score representing cancer patient All IHC images captured cid2 400 Leica compound microscope DC500 camera Statistical analysis Descriptive statistics including mean sd median range frequency summarise data Table 1 Spearmans correlation coefficients computed explore correlations clinicopathological variables biomarker variables Table 3 Survival time calculated days date surgery date death censored date final contact 1 October 2007 patients lost followup Survival curves analysed KaplanMeier method In univariate analysis logrank test calculate difference survival categorical variables Cox proportional hazards PH model examine effect survival continuous variables Multivariate survival analysis carried Cox PH models controlling clinicopathological predictors The PH assumptions verified logtransformation plot goodnessoffit models checked martingale deviance residual plots The timedependent receiver operating characteristic survival ROC applied display compare sensitivity specificity predictive models based multivariate survival analysis Heagerty Zheng 2005 The survival ROC curves accommodate time dependent nature censoring survival data All Pvalues twosided A Pvalue 005 considered statistically significant The statistical plots generated SAS software Version 913 SAS Institute Inc Cary NC USA R software Version 261 R Foundation Statistical Computing Vienna Austria RESULTS SIAH specifically decorates proliferating tumour cells human pancreatic cancer As downstream signalling gate keeper identified KRAS pathway Figure 1A SIAH logical potent antiKRAS drug target cancer Schmidt et al 2007 Ahmed et al 2008 SIAHpositive cells pancreatic tumours epithelial origin adult pancreas SIAH wwwbjcancercom DOI101038bjc2014659 515 BRITISH JOURNAL OF CANCER Hypoxia reduces prognosis pancreatic cancer Table 1 Demographic clinical biomarker variables pancreatic cancerpatient survival Variables Age surgery year Gender Surgical procedure Complete resection Tumour size Lymph node status Positive margin UICC stage Tumour grade Extension Perineural invasion Angiolymphatic invasion Adjuvant therapy chemotherapy radiation therapy Biomarkers EGFR SIAH Ki67 PhosphoERK HIF1a Survival Vital status Level Mean Male Female Standard pancreaticoduodenectomy Pyloruspreserving pancreaticoduodenectomy Distal pancreatectomy Total pancreatectomy Missing No Yes Mean p2 cm 42 cm N0 N1 R0 R1R2 Stage IA Stage IB Stage IIA Stage IIBIV 2 3 4 No Yes Missing No Yes Missing No Yes Missing No Yes Number patients 123 127 119 131 100 Median time days Alive Dead Meanfrequency 631 80 67 77 52 8 10 1 19 127 29 44 103 74 73 127 20 12 18 43 74 38 73 36 58 89 18 74 55 18 98 31 7 26 115 279 4230 3933 3622 3827 541 19 128 sd Pvaluea 0077 0530 0542 0584 0164 0343 0461 0703 o0001 0284 0696 0253 0883 0556 0235 0171 0185 0005 120 544 456 524 344 54 68 13 87 115 209 701 503 497 864 136 82 122 292 504 259 497 245 395 605 574 426 760 240 184 816 152 2211 2422 2814 3312 460 615 129 871 Logrank test categorical variables Cox proportional hazards model continuous variables predominantly nuclear expression pattern highly specific tumour cells Figure 1B D SIAH staining detected normal pancreas pancreatitis tissues tumour stroma infiltrating immune cells Figure 1D data shown Numbers SIAHpositive tumour cells increase human pancreatic tumours progress welldefined neoplastic stagesPanIN1 PanIN2 PanIN3 ADCAs Figure 1B D 2B correlating SIAH expression active tumour proliferation Therefore SIAHdependent proteolysis proliferat ing tumour cells facilitate oncogenic KRAS signalling 516 wwwbjcancercom DOI101038bjc2014659 Hypoxia reduces prognosis pancreatic cancer BRITISH JOURNAL OF CANCER Table 2 IHC staining biomarkers KRASKi67HIF1a pathways Biomarker EGFR Total samples stained 249 Positive samples 192 77 Total patients stained 110 Positive patients 94 85 Median expression range positive samples 2 04 HER2 pERK SIAH Ki67 HIF1a 287 301 315 250 210 56 19 219 72 303 96 237 95 143 69 117 131 127 119 100 32 27 106 81 127 100 118 99 77 77 0 02 40 590 30 590 40 590 40 290 Abbreviations HIF1a ¼ hypoxiainducible factor 1a IHC ¼ immunohistochemical Table 3 Spearmans correlation coefficients clinical variables biomarkers Biomarker Lymph node Pathological grade Extension Tumour size EGFR SIAH Ki67 PhosphoERK HIF1a Lymph node Pathological grade Extension Tumour size EGFR SIAH Ki67 PhosphoERK HIF1a 1 011 cid3 014 1 022 016 011 cid3 010 022 1 017 1 1 014 1 076 1 1 cid3 013 012 1 Abbreviation HIF1a ¼ hypoxiainducible factor 1a Note coefficients X010 p cid3 010 shown significantly different 0 bold making SIAH useful tumourspecific biomarker pancreatic cancer antiphosphoERK The IHC staining signalling components KRAS pathway Tumour biospecimens stained antiEGFR antiHER2 antiSIAH antibodies Figure 1C D Table 2 data shown The membrane receptors EGFR HER2 evaluated extent intensity staining scale 04 heterogeneous expression Table 2 EGFR expression summarised Figure 1C D Table 2 Most tumour samples appreciable HER2 expression Table 2 Thus HER2 excluded statistical analyses PhosphoERK staining scored staining percentage scale 0100 positivity PhosphoERK expression observed nuclei tumour cells adjacent tumour stroma SIAH staining scored staining percentage scale 0100 positivity Figure 1C D Table 2 For pancreatic cancer patients SIAH expression detected 100 EGFR expression detected 85 phosphoERK expression detected 81 Table 2 resected tumours SIAH EGFR phosphoERK In marked 98 neoplastic cells In 234 TMA tumour cores retained highquality IHC staining EGFR phospho ERK SIAH SIAH marked 79 EGFR marked 70 phosphoERK marked 62 tumour cells Figure 1C Table 2 The results signalling components KRAS pathway pertinent biomarkers pancreatic cancer Increased expression HIF1a associated shortened survival post surgery HIF1a expression examined assess hypoxic response pancreatic tumours HIF1a staining scored staining percentage scale 290 Figure 2D Table 2 HIF1a expression heterogeneous The greatest level expression concentrated nucleus pancreatic cancer cells low cytoplasmic expression levels detected Representative HIF1a staining patients distinct survival rates shown Figure 2D The median expression level HIF1a 40 Patients expressing HIF1a 40 median survival time 148 months patients expressing HIF1a 40 median survival time 192 months P ¼ 0004 Figure 2C Only 133 patients high HIF1a expression survived 3 years longer Patients HIF1a median 40 expression showed statistically significant increase 5year survival compared patients high HIF1a expression Figure 2C D The IHC staining Ki67 resectable pancreatic cancer The tumour proliferation index measured Ki67 staining scored percentage scale 590 positivity Figure 2F Table 2 Only patient display detectable Ki67 staining Ki67 expressed tumourcancerous cells tumour stroma immune cells showed Ki67positive staining Ki67 expression increased pathological grades Figure 2F marking proliferat ing tumour cells pancreatic cancer The median expression level Ki67 40 The median survival 146 months patients expressing Ki67 40 187 months patients expressing Ki67 40 Figure 2E F Only 153 patients high Ki67 expression survived 3 years longer vs 286 survival rate patients low Ki67 expression results statistically significant P ¼ 0146 Figure 2E A combination clinicopathologic predictors biomarkers associated improved accuracy predict patient survival post surgery For clinical variables prognostic pancreatic cancer univariate analysis showed tumour grade Po0001 significant prognostic predictor patient survival KaplanMeier survival curves indicated increased tumour grade associating poor survival Figure 2A Other clinical variables including lymph node status tumour extension pancreas UICC clinical stage margin status perineural invasion angiolymphatic invasion adjuvant therapy Table 1 significant prognostic factors patient survival wwwbjcancercom DOI101038bjc2014659 517 BRITISH JOURNAL OF CANCER Hypoxia reduces prognosis pancreatic cancer Human pancreatic cancer SIAH expression human pancreatic cancer 95 CI ADCA marker expression 234 samples evaluated SIAH 79 Upstream pathway component EGFRHER2 70 60 PY YP Kras GTP RAF MAPKKK MEK MAPKK p00001 PanIN ADCA versus normal tissue P 00020 P 00061 P 00001 P 00001 P 00003 P 00001 P 00462 P 00236 40 n 50 o s s e r p x E 30 20 10 0 N m al n7 P IN I n35 P IN II n20 P IN III n15 A D C A 2 n84 A D C A 3 n161 A D C A 4 n33 PhosphoERK 62 34 6 44 24 85 21 13 EGFR 70 Normal Pan IN I Pan IN II Pan IN III ADCA grade 2 ADCA grade 3 ADCA grade 4 ERK MAPK Midstream pathway component ETS SIAH Downstream pathway component Tumorigenesis metastasis HE SIAH pERK EGFR Figure 1 EGFR phosphoERK SIAH expression resectable pancreatic cancer A A schematic illustration oncogenic KRAS pathway shown The expression upstream receptors EGFRHER2 midstream kinase ERK downstream E3 ligase SIAH examined B SIAH expression upregulated human pancreatic cancer progresses advanced stages Percentage SIAH þ cells increased progressively welldefined stages PanIN1 PanIN2 PanIN3 adenocarcinoma ADCA 2 ADCA 3 ADCA 4 Students ttests performed Pvalues 005 considered statistically significant shown C Venn diagram representation single double triple staining SIAH phosphoERK EGFR expression 234 tumour cores complete overlapping set IHC staining shown D Representative EGFR phosphoERK SIAH staining PanIN ADCA stages shown SIAH marked tumour cells specifically Note lack SIAH staining normal pancreas tumour stroma Univariate analysis Cox proportional hazards model showed HIF1a expression increased power predict survival HIF1a expression significant predictor survival P ¼ 0005 hazard ratio 119 95 CI 106135 unit 20 increment indicating higher percentage HIF1a expression associated reduced survival Table 1 Pvalue logrank test binary HIF1a expression equal 40 shown Figure 2C None biomarkers EGFR SIAH phosphoERK Ki67 significant predictors survival pancreatic cancer individually Table 1 The analysis data set varies slightly biomarker minor TMA imperfections Table 2 HIF1a expression correlated tumour grade Spearmans rank correlation coefficient 022 P ¼ 0025 significantly correlated clinicopathological predictors Table 3 Ki67 expression highly correlated SIAH Spearmans rank correlation coefficient 076 Po0001 correlated significantly clinical variables Table 3 The statistically significant correlation tumour grade tumour size Spearmans rank correlation coefficient 022 P ¼ 0008 Table 3 To determine addition molecular biomarkers improve prognostic accuracy adjusting clinicopathological variables performed multiple survival analyses Cox PH regression models After adjusting lymph node status pathologic grade tumour extension pancreas tumour size signalling components KRAS pathway EGFR phosphoERK SIAH statistically significant predictors patient survival Table 4 Pathological grade remained significant prognostic factor Cox PH regression model Ki67 HIF1a expression trended reach statistical significance P ¼ 0247 P ¼ 0149 respectively Table 4 One possible explanation disap pearance significance HIF1a expression univariate multivariate analysis HIF1a analysis significantly correlated pathological tumour grade In exploratory analysis HIF1a expression statistically tumour grade significant intentionally removed P ¼ 0004 pathological Survival ROC curves Consistent previous reports clinical variables tumour size pathologic grade linked survival pancreatic cancer Tables 1 4 Our biomarker analysis revealed HIF1a expression associated reduced survival pancreatic cancer Here proposed models predicting patient survival A biomarkers Ki67 HIF1a EGFR phosphoERK SIAH B clinicopathologic C clinicopathologic variables plus Ki67 D clinicopatho logic variables plus HIF1a E clinicopathologic variables plus biomarkers To evaluate predictive accuracy models timedependent survival ROC curves constructed 3year survival predictions Figure 3A Area curve AUC 3year survival numerically compare performance models The AUC increased 0685 biomarkers Model A 0751 clinicopathologic variables Model B 0773 addition Ki67 Model C 0788 addition HIF1a Model D respectively Figure 3B The AUC combining clinico pathological variables plus molecular biomarkers Model E 0850 Figure 3B A timedependent AUCt curve continuous time points plotted investigate predictive accuracy models survival The data suggest absent decreased HIF1a 518 wwwbjcancercom DOI101038bjc2014659 Hypoxia reduces prognosis pancreatic cancer BRITISH JOURNAL OF CANCER Tumour grade Grade 2 Grade 3 Grade 4 Logrank test P 0001 SIAH l v r u S 10 08 06 04 02 00 0 2 4 6 8 10 12 Year surgery Grade 2 Pt Grade 3 Pt Grade 4 Pt 38 73 36 21 24 6 14 14 3 12 9 3 5 5 2 5 3 1 2 1 0 Normal PanIN ADCA grade 3 Tissue microarray grade 3 ADCA 10 08 l v r u S 06 04 02 00 HIF1αcid240 Pt HIF1α 40 Pt l v r u S 10 08 06 04 02 00 HIF1a expression HIF1cid2cid240 HIF1cid2 40 HE Logrank test P 0004 HIF1cid2 0 2 4 6 8 10 12 Year surgery Survival 10 year post surgery Survival near median Survival 1 year 55 23 16 13 3 45 4 9 5 1 4 1 2 1 Ki67 expression Ki67cid240 Ki67 40 Logrank test P 0166 HE Ki67 0 2 4 6 8 10 12 Year surgery Ki67cid240 Pt Ki67 40 Pt 70 26 49 13 16 12 7 5 5 3 3 2 1 1 Normal ADCA grade 2 ADCA grade 3 ADCA grade 4 Figure 2 Increased tumour grades heightened hypoxia response predicts poor prognosis adverse outcome resectable pancreatic cancer KaplanMeier curves predict patient survival number patients risk year 12 years followup indicated A C E Representative IHC images shown B D F Haematoxylin eosin HE staining shown view tissue histology A KaplanMeier curve shows tumour grade significant predictor patient survival Po0001 By univariate analysis higher tumour grade associated worse prognosis B Representative SIAH expression shown normal pancreas PanINs ADCAs C The KaplanMeier curve shows increased HIF1a expression correlated reduced survival pancreatic cancer D The representative HIF1a staining shown Grade 3 ADCA These patients similar clinicopathological diagnoses experienced markedly different outcomes survival Increased HIF1a expression appears correlated reduced survival pancreatic cancer E The KaplanMeier curves patients Ki67 staining median expression level 40 shown F Representative images Ki67 staining normal pancreas ADCA 2 3 4 shown Increased Ki67 expression associated advanced stages ADCAs associated good prognosis longterm survival combination molecular biomarkers EGFR phospho ERK SIAH Ki67 HIF1a KRASHIF1a pathway clinicopathologic variables tumour size pathological grade margin lymph node status improve prognostic accuracy patient survival post surgery Figure 3B DISCUSSION Ninetyfive percent mortality rates pancreatic cancer shown little improvement despite intense research efforts 40 years Patient prognosis appears influenced large pancreatic tumour genome biology cancer cell dissemination adequate resection Wolfgang et al 2013 Favourable clinicopathological prognostic indicators include small tumour size negative nodal status negative resection margin welldifferentiated carcinomas Evaluation numer ous molecular biomarkers prognostic factors achieved inconsistent results Sawyers 2008 Costello et al 2012 Winter et al 2013 Discovery validation logical useful biomarkers improve prognosis guide effective therapies important combat pancreatic cancer Here report SIAH tumourspecific biomarker pancreatic cancer Figure 1 HIF1a shows promise prognostic variable Figure 2 individually selected biomarkers EGFR phosphoERK SIAH Ki67 HIF1a weakly prognostic combined clinicopatho logical predictors tumour size pathological grade margin status wwwbjcancercom DOI101038bjc2014659 519 BRITISH JOURNAL OF CANCER Hypoxia reduces prognosis pancreatic cancer cancer lymph node status yields increased prognostic accuracy resectable pancreatic Figure 3 One important caveat resected pancreatic tumours examined study As B85 pancreatic cancer patients incurable diseases surgical options know KRASKi67HIF1a pathway biomarkers synergise clinicopathologic predictors inoperable pan creatic cancers With rapid autopsy programmes pancreatic cancer hope analyse validate findings HIF1a EGFR phosphoERK SIAH Ki67 combination clinical parameters context systemic metastasis future We demonstrated increased HIF1a expression correlates increasing pathological grades consistent previous findings pancreatic cancer Kitada et al 2003 Shibaji et al 2003 Guillaumond et al 2013 HIF1a overexpression negative prognostic variable human cancers Semenza 2003 Wilson Hay 2011 Here demonstrate increased HIF1a expression correlates increasing pathological grades poor prognosis HIF1a overexpressed 69 pancreatic tumour specimens study 147 patients consistent results prior smallscale studies Zhong et al 1999 Kitada et al 2003 In study HIF1a overexpressed primary pancreatic cancer specimens Zhong et al 1999 In second study overexpression HIF1a detected 592 29 49 cases pancreatic cancer specimens Kitada et al 2003 Previous studies correlations HIF1a expression larger tumour size advanced UICC stage metastatic disease pancreatic cancer Kitada et al 2003 Shibaji et al 2003 Chang et al 2011 Our results shown high HIF1a expression levels pancreatic adenocarcinomaswith staining percentages 40signify notable decrease patient survival Furthermore survival ROC analysis suggests adding HIF1a expression list existing clinicopathologic parameters strengthen clinical prediction survival pancreatic cancer AUC 0751 vs 0788 Figure 3 The data suggest decreased Ki67 good prognosis shortterm survival year lack decreased HIF1a good prognosis longterm survival The different onset distinct dynamics Ki67 HIF1a expression patterns reflect altered biology successful adaptation pancreatic cancer cells Table 4 Cox PH regression models clinical variables biomarkers Predictors Lymph node positive Pathological grade Extension Tumour size EGFR SIAH Ki67 PhosphoERK HIF1a Level No Yes 2 3 4 No Yes Hazard ratio 1000 0915 95 CI 0536 1000 2665 3944 1000 1280 1180 1056 0998 1010 0997 1005 1329 1736 0748 0907 0895 0980 0993 0989 0998 Pvalue 1560 5340 8960 2190 1530 1250 1020 1030 1000 1010 0745 0006 0001 0368 0219 0519 0822 0247 0443 0149 Abbreviations CI ¼ confidence interval HIF1a ¼ hypoxiainducible factor 1a Timedependent survival ROCs 3 years Area curve plots 5 years y t v t s n e S 10 08 06 04 02 00 Five biomarkers Clinical predictors Clinical Ki67 Clinical HIF1cid2 Clinical biomarkers C U A 10 09 08 07 06 05 Five biomarkers 0685 Clinical variables 0751 Clinical Ki67 0773 Clinical HIF1cid2 0788 Clinical biomarkers 0850 00 02 04 06 1specificity 08 10 0 1 2 3 4 5 Year surgery Figure 3 A combination clinical markers biomarkers accurate prognostic value predicting 3 5year patient survival resectable pancreatic cancer A Threeyear survival prediction timedependent survival ROCs 3 years based predictive models shown Five biomarkers black line clinicopathological predictors red dotted line served controls Ki67 combination clinical predictors green dotted line improved predictive power HIF1a combination clinical predictors blue dotted line When biomarkers combined clinical predictors aquacyan dotted line significant improvement predicting patient survival postpancreatic surgeries B Fiveyear survival prediction AUCt plots 5 years based predictive models shown black line Five biomarkers black line clinicopathological predictors red dotted line served controls Ki67 combination clinical predictors green dotted line improved predictive power HIF1a blue dotted line When biomarkers combined clinical predictors aquacyan dotted line significant improvement predictive power based AUC analysis 520 wwwbjcancercom DOI101038bjc2014659 Hypoxia reduces prognosis pancreatic cancer BRITISH JOURNAL OF CANCER local environments course aggressive tumour growth metastasis vivo Taken results support notion HIF1a expression useful prognostic indictor adverse clinical outcome resectable pancreatic cancer role Ki67 prognostic marker Ki67 widely expressed pancreatic tumours 95 evaluated study Two previous studies investigated pancreatic adenocarcinomas negative results Stanton et al 2003 Lebe et al 2004 tumour specimens taken fewer 60 patients In larger study n ¼ 147 KaplanMeier survival analysis reveal statistically significant difference 5year survival patients low high levels Ki67 expression P ¼ 0166 consistent previous reports Figure 2E Through multivariate analysis significant correlation exists overexpression HIF1a decreased postoperative survival Besides HIF1a addition Ki67 additional biomarkers EGFR phosphoERK SIAH oncogenic KRAS signalling pathway upstream midstream downstream signalling modules respec tively increase accuracy prognosis patient survival Hyperactive KRAS signalling major menace human pancreatic cancer Currently oncogenic KRAS remained undruggable target cancer Additional studies validate prognostic values combination clinicopatho logical predictors RAS pathway biomarkers assist predict patient survival surgical resection future ACKNOWLEDGEMENTS We indebted Drs Edward Leof Stephen Deutsch Edward Johnson Frank Lattanzio Roger Perry Richard Hoefer Vasilena Zheleva Mr John Crooks Ms Lauren Siewertsz van Reesema critical reading manuscript invaluable critiques RLS supported Mayo Clinic Pobanz Family Predoctoral Research Fellowship This work supported 2010 AACRPanCAN Innovative Grant AACRPanCan 169458 2005 Lustgarten Foundation Pancreatic Cancer Research RFA05046 National Institute General Medical Sciences GM06992206S1 National Cancer CA140550 Mayo Pancreatic Cancer SPORE Pilot Grant Award AHT Institute CONFLICT OF INTEREST The authors declare conflict AUTHOR CONTRIBUTION RQ conducted biostatistical analyses TCS identified representative tumour paraffin blocks guided pancreatic TMA construction controlled quality IHC staining scoring NRR reviewed patient charts extracted clinical data Mayo Clinic tumour registry established database RLS assisted patient deidentification data entry data processing IHC image capture TS assisted clinical data extraction STC recruited identified pancreatic cancer patients clinical studies GMP oversaw Mayo Clinic Pancreatic SPORE operations provided TMA slides scientific guidance study AHT designed experiments supervised project wrote manuscript generated figures tables All authors discussed results contributed extensive revisions manuscript REFERENCES Ahmed AU Schmidt RL Park CH Reed NR Hesse SE Thomas CF Molina JR Deschamps C Yang P Aubry MC Tang AH 2008 Effect disrupting seveninabsentia homolog 2 function lung cancer cell growth J Natl Cancer Inst 10022 16061629 Akakura N Kobayashi M Horiuchi I Suzuki A Wang J Chen J Niizeki H Kawamura K Hosokawa M Asaka M 2001 Constitutive expression hypoxiainducible factor1alpha renders pancreatic cancer cells resistant apoptosis induced hypoxia nutrient deprivation Cancer Res 6117 65486554 Ardito CM Gruner BM Takeuchi KK LubesederMartellato C Teichmann N Mazur PK Delgiorno KE Carpenter ES Halbrook CJ Hall JC Pal D Briel T Herner A TrajkovicArsic M Sipos B Liou GY Storz P Murray NR Threadgill DW Sibilia M Washington MK Wilson CL Schmid RM Raines EW Crawford HC Siveke JT 2012 EGF receptor required KRASinduced pancreatic tumorigenesis Cancer Cell 223 304317 Chang Q Jurisica I Do T Hedley DW 2011 Hypoxia predicts aggressive growth spontaneous metastasis formation orthotopically grown primary xenografts human pancreatic cancer Cancer Res 718 31103120 Conroy T Desseigne F Ychou M Bouche O Guimbaud R Becouarn Y Adenis A Raoul JL GourgouBourgade S la Fouchardiere C Bennouna J Bachet JB KhemissaAkouz F PereVerge D Delbaldo C Assenat E Chauffert B Michel P MontotoGrillot C Ducreux M 2011 FOLFIRINOX versus gemcitabine metastatic pancreatic cancer N Engl J Med 36419 18171825 Costello E Greenhalf W Neoptolemos JP 2012 New biomarkers targets pancreatic cancer application treatment Nat Rev Gastroenterol Hepatol 98 435444 Guillaumond F Leca J Olivares O Lavaut MN Vidal N Berthezene P Dusetti NJ Loncle C Calvo E Turrini O Iovanna JL Tomasini R Vasseur S 2013 Strengthened glycolysis hypoxia supports tumor symbiosis hexosamine biosynthesis pancreatic adenocarcinoma Proc Natl Acad Sci USA 11010 39193924 Heagerty PJ Zheng Y 2005 Survival model predictive accuracy ROC curves Biometrics 611 92105 Hidalgo M 2010 Pancreatic cancer N Engl J Med 36217 16051617 Hruban RH Goggins M Parsons J Kern SE 2000 Progression model pancreatic cancer Clin Cancer Res 68 29692972 Javle MM Gibbs JF Iwata KK Pak Y Rutledge P Yu J Black JD Tan D Khoury T 2007 Epithelialmesenchymal transition EMT activated extracellular signalregulated kinase pErk surgically resected pancreatic cancer Ann Surg Oncol 1412 35273533 Katz MH Wang H Fleming JB Sun CC Hwang RF Wolff RA Varadhachary G Abbruzzese JL Crane CH Krishnan S Vauthey JN Abdalla EK Lee JE Pisters PW Evans DB 2009 Longterm survival multidisciplinary management resected pancreatic adenocarcinoma Ann Surg Oncol 164 836847 Kitada T Seki S Sakaguchi H Sawada T Hirakawa K Wakasa K 2003 Clinicopathological significance hypoxiainducible factor1alpha expression human pancreatic carcinoma Histopathology 436 550555 Lebe B Sagol O Ulukus C Coker A Karademir S Astarcioglu H Kupelioglu A Astarcioglu I Obuz F 2004 The importance cyclin D1 Ki67 expression biological behavior pancreatic adenocarcinomas Pathol Res Pract 2005 389396 Maitra A Hruban RH 2008 Pancreatic cancer Annu Rev Pathol 3 157188 Sawyers CL 2008 The cancer biomarker problem Nature 4527187 548552 Schmidt RL Park CH Ahmed AU Gundelach JH Reed NR Cheng S Knudsen BE Tang AH 2007 Inhibition RASmediated transformation tumorigenesis targeting downstream E3 ubiquitin ligase seven absentia homologue Cancer Res 6724 1179811810 SeboltLeopold JS Herrera R 2004 Targeting mitogenactivated protein kinase cascade treat cancer Nat Rev Cancer 412 937947 Semenza GL 2003 Targeting HIF1 cancer therapy Nat Rev Cancer 310 721732 Shibaji T Nagao M Ikeda N Kanehiro H Hisanaga M Ko S Fukumoto A Nakajima Y 2003 Prognostic significance HIF1 alpha overexpression human pancreatic cancer Anticancer Res 236C 47214727 wwwbjcancercom DOI101038bjc2014659 521 BRITISH JOURNAL OF CANCER Hypoxia reduces prognosis pancreatic cancer Siegel R Naishadham D Jemal A 2013 Cancer statistics 2013 CA Cancer J Vogelstein B Papadopoulos N Velculescu VE Zhou S Diaz Jr LA Clin 631 1130 Sohn TA Yeo CJ Cameron JL Koniaris L Kaushal S Abrams RA Sauter PK Coleman J Hruban RH Lillemoe KD 2000 Resected adenocarcinoma pancreas616 patients results outcomes prognostic indicators J Gastrointest Surg 46 567579 Kinzler KW 2013 Cancer genome landscapes Science 3396127 15461558 Von Hoff DD Korn R Mousses S 2009 Pancreatic cancercould simple A different context vulnerability Cancer Cell 161 78 Wilson WR Hay MP 2011 Targeting hypoxia cancer therapy Nat Rev SpivakKroizman TR Hostetter G Posner R Aziz M Hu C Demeure MJ Cancer 116 393410 Von Hoff D Hingorani SR Palculict TB Izzo J Kiriakova GM Abdelmelek M Bartholomeusz G James BP Powis G 2013 Hypoxia triggers hedgehogmediated tumorstromal interactions pancreatic cancer Cancer Res 7311 32353247 Stanton KJ Sidner RA Miller GA Cummings OW Schmidt CM Howard TJ Wiebke EA 2003 Analysis Ki67 antigen expression DNA proliferative fraction survival resected cancer pancreas Am J Surg 1865 486492 Valle JW Palmer D Jackson R Cox T Neoptolemos JP Ghaneh P Rawcliffe CL Bassi C Stocken DD Cunningham D OReilly D Goldstein D Robinson BA Karapetis C Scarfe A Lacaine F Sand J Izbicki JR Mayerle J Dervenis C Olah A Butturini G Lind PA Middleton MR Anthoney A Sumpter K Carter R Buchler MW 2014 Optimal duration timing adjuvant chemotherapy definitive surgery ductal adenocarcinoma pancreas ongoing lessons ESPAC3 study J Clin Oncol 326 504512 Winter JM Yeo CJ Brody JR 2013 Diagnostic prognostic predictive biomarkers pancreatic cancer J Surg Oncol 1071 1522 Wolfgang CL Herman JM Laheru DA Klein AP Erdek MA Fishman EK Hruban RH 2013 Recent progress pancreatic cancer CA Cancer J Clin 635 318348 Zhong H De Marzo AM Laughner E Lim M Hilton DA Zagzag D Buechler P Isaacs WB Semenza GL Simons JW 1999 Overexpression hypoxiainducible factor 1alpha common human cancers metastases Cancer Res 5922 58305835 This work published standard license publish agree ment After 12 months work freely available license terms switch Creative Commons Attribution NonCommercialShare Alike 40 Unported License 522 wwwbjcancercom DOI101038bjc2014659